VIPR2
| Vasoactive intestinal peptide receptor 2 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Identifiers | |||||||||||
| Symbols | VIPR2 ; FLJ16511; VPAC2 | ||||||||||
| External IDs | Template:OMIM5 Template:MGI HomoloGene: 2540 | ||||||||||
| |||||||||||
| RNA expression pattern | |||||||||||
| File:PBB GE VIPR2 205946 at tn.png | |||||||||||
| File:PBB GE VIPR2 205947 s at tn.png | |||||||||||
| File:PBB GE VIPR2 211598 x at tn.png | |||||||||||
| More reference expression data | |||||||||||
| Orthologs | |||||||||||
| Template:GNF Ortholog box | |||||||||||
| Species | Human | Mouse | |||||||||
| Entrez | n/a | n/a | |||||||||
| Ensembl | n/a | n/a | |||||||||
| UniProt | n/a | n/a | |||||||||
| RefSeq (mRNA) | n/a | n/a | |||||||||
| RefSeq (protein) | n/a | n/a | |||||||||
| Location (UCSC) | n/a | n/a | |||||||||
| PubMed search | n/a | n/a | |||||||||
Vasoactive intestinal peptide receptor 2, also known as VIPR2, is a human gene.[1]
Vasoactive intestinal peptide (VIP; MIM 192320) and pituitary adenylate cyclase activating polypeptide (PACAP; MIM 102980) are homologous peptides that function as neurotransmitters and neuroendocrine hormones. While the receptors for VIP and PACAP share homology, they differ in their substrate specificities and expression patterns. See VIPR1 (MIM 192321) and ADCYAP1R1(MIM 102981).[supplied by OMIM][1]
See also
References
Further reading
- Goetzl EJ, Pankhaniya RR, Gaufo GO; et al. (1998). "Selectivity of effects of vasoactive intestinal peptide on macrophages and lymphocytes in compartmental immune responses". Ann. N. Y. Acad. Sci. 840: 540–50. PMID 9629281.
- Adamou JE, Aiyar N, Van Horn S, Elshourbagy NA (1995). "Cloning and functional characterization of the human vasoactive intestinal peptide (VIP)-2 receptor". Biochem. Biophys. Res. Commun. 209 (2): 385–92. PMID 7733904.
- Svoboda M, Tastenoy M, Van Rampelbergh J; et al. (1995). "Molecular cloning and functional characterization of a human VIP receptor from SUP-T1 lymphoblasts". Biochem. Biophys. Res. Commun. 205 (3): 1617–24. PMID 7811244.
- Inagaki N, Yoshida H, Mizuta M; et al. (1994). "Cloning and functional characterization of a third pituitary adenylate cyclase-activating polypeptide receptor subtype expressed in insulin-secreting cells". Proc. Natl. Acad. Sci. U.S.A. 91 (7): 2679–83. PMID 8146174.
- Xia M, Gaufo GO, Wang Q; et al. (1996). "Transduction of specific inhibition of HuT 78 human T cell chemotaxis by type I vasoactive intestinal peptide receptors". J. Immunol. 157 (3): 1132–8. PMID 8757618.
- Wei Y, Mojsov S (1997). "Tissue specific expression of different human receptor types for pituitary adenylate cyclase activating polypeptide and vasoactive intestinal polypeptide: implications for their role in human physiology". J. Neuroendocrinol. 8 (11): 811–7. PMID 8933357.
- Mackay M, Fantes J, Scherer S; et al. (1997). "Chromosomal localization in mouse and human of the vasoactive intestinal peptide receptor type 2 gene: a possible contributor to the holoprosencephaly 3 phenotype". Genomics. 37 (3): 345–53. PMID 8938447.
- Nicole P, Du K, Couvineau A, Laburthe M (1998). "Site-directed mutagenesis of human vasoactive intestinal peptide receptor subtypes VIP1 and VIP2: evidence for difference in the structure-function relationship". J. Pharmacol. Exp. Ther. 284 (2): 744–50. PMID 9454823.
- Dewit D, Gourlet P, Amraoui Z; et al. (1998). "The vasoactive intestinal peptide analogue RO25-1553 inhibits the production of TNF and IL-12 by LPS-activated monocytes". Immunol. Lett. 60 (1): 57–60. PMID 9541464.
- Lutz EM, Shen S, Mackay M; et al. (1999). "Structure of the human VIPR2 gene for vasoactive intestinal peptide receptor type 2". FEBS Lett. 458 (2): 197–203. PMID 10481065.
- Busto R, Prieto JC, Bodega G; et al. (2000). "Immunohistochemical localization and distribution of VIP/PACAP receptors in human lung". Peptides. 21 (2): 265–9. PMID 10764955.
- Nicole P, Lins L, Rouyer-Fessard C; et al. (2000). "Identification of key residues for interaction of vasoactive intestinal peptide with human VPAC1 and VPAC2 receptors and development of a highly selective VPAC1 receptor agonist. Alanine scanning and molecular modeling of the peptide". J. Biol. Chem. 275 (31): 24003–12. doi:10.1074/jbc.M002325200. PMID 10801840.
- Bajo AM, Juarranz MG, Valenzuela P; et al. (2001). "Expression of vasoactive intestinal peptide (VIP) receptors in human uterus". Peptides. 21 (9): 1383–8. PMID 11072126.
- Lara-Marquez M, O'Dorisio M, O'Dorisio T; et al. (2001). "Selective gene expression and activation-dependent regulation of vasoactive intestinal peptide receptor type 1 and type 2 in human T cells". J. Immunol. 166 (4): 2522–30. PMID 11160313.
- Lara-Marquez ML, O'Dorisio MS, Karacay B (2001). "Vasoactive intestinal peptide (VIP) receptor type 2 (VPAC2) is the predominant receptor expressed in human thymocytes". Ann. N. Y. Acad. Sci. 921: 45–54. PMID 11193874.
- Groneberg DA, Hartmann P, Dinh QT, Fischer A (2001). "Expression and distribution of vasoactive intestinal polypeptide receptor VPAC(2) mRNA in human airways". Lab. Invest. 81 (5): 749–55. PMID 11351046.
- Juarranz MG, Bolaños O, Gutiérrez-Cañas I; et al. (2002). "Neuroendocrine differentiation of the LNCaP prostate cancer cell line maintains the expression and function of VIP and PACAP receptors". Cell. Signal. 13 (12): 887–94. PMID 11728828.
- Fischer TC, Dinh QT, Peiser C; et al. (2002). "Simultaneous detection of receptor mRNA and ligand protein in human skin tissues". J. Cutan. Pathol. 29 (2): 65–71. PMID 12150135.
- Strausberg RL, Feingold EA, Grouse LH; et al. (2003). "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences". Proc. Natl. Acad. Sci. U.S.A. 99 (26): 16899–903. doi:10.1073/pnas.242603899. PMID 12477932.
This article incorporates text from the United States National Library of Medicine, which is in the public domain.